Table 2.
Relationships between microvessel invasion and clinicopathological features in the discovery cohort
| Variables | Microvessel invasion | ||
|---|---|---|---|
| Yes (n = 389) | No (n = 1151) | P | |
| Age, year | 52.1 ± 11.6 | 53.3 ± 11.7 | 0.082 |
| Gender, male/female | 332 (85.3%)/57 (14.7%) | 973 (84.5%)/178 (15.5%) | 0.700 |
| Hepatitis B history, yes/no | 317 (83.6%)/62 (16.4%) | 938 (83.0%)/192 (17.0%) | 0.776 |
| ALT, U/L | 54.4 ± 84.7 | 50.7 ± 64.6 | 0.370 |
| γ-GT, U/L | 94.3 ± 84.9 | 86.9 ± 92.7 | 0.168 |
| Albumin, g/L | 40.9 ± 4.9 | 41.6 ± 4.6 | 0.010 |
| Liver cirrhosis, yes/no | 312 (81.0%)/73 (19.0%) | 956 (84.3%)/178 (15.7%) | 0.153 |
| α-Fetoprotein (>200/≤200 ng/dL) | 191 (49.1%)/198 (50.9%) | 402 (34.9%)/749 (65.1%) | <0.001 |
| Tumor size, cm | 6.5 ± 3.8 | 4.9 ± 3.3 | <0.001 |
| Tumor size (>5 cm/≤5 cm) | 195 (50.1%)/194 (49.9%) | 370 (32.1%)/781 (67.9%) | <0.001 |
| Tumor number, solitary/multiple | 332 (85.3%)/57 (14.7%) | 1009 (87.7%)/142 (12.3%) | 0.239 |
| Tumor encapsulation, complete/no | 166 (42.9%)/221 (57.1%) | 637 (55.4%)/512 (44.6%) | <0.001 |
| Tumor differentiation, I–II/III–IV | 232 (59.9%)/155 (40.1%) | 866 (76.5%)/266 (23.5%) | <0.001 |
| BCLC stage, 0/A/B | 24 (6.2%)/312 (80.2%)/53 (13.6%) | 170 (14.8%)/880 (76.5%)/101 (8.8%) | <0.001* |
*, P trend. Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, γ-GT γ-glutamyl transpeptidase